Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 4/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | CDK4 | P11802 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | WNT1 | P04628 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808938 | 0.70 | CXCR4 (0.53) | CYP3A4HTR2C | |
| SCHEMBL29549874 | 0.67 | CYP3A4 (0.44) | CYP3A4HTR2C | |
| SCHEMBL16217182 | 0.67 | CYP3A4 (0.41) | CYP3A4HTR2C | |
| SCHEMBL23530014 | 0.67 | CYP3A4 (0.44) | CYP3A4HTR2C | |
| SCHEMBL23243011 | 0.67 | PDE1B (0.36) | PDE10AJAK2JAK1TLR7METTL3 | |
| SCHEMBL23263472 | 0.67 | PDE1B (0.36) | PDE10AJAK2JAK1TLR7METTL3 | |
| Hydrochloric Acid SCHEMBL2913328 | 0.64 | HTR2C (0.40) | CYP3A4HTR2C | |
| SCHEMBL16168344 | 0.64 | HTR2C (0.44) | CYP3A4HTR2CCDK4 | |
| SCHEMBL5776366 | 0.64 | CYP3A4 (0.38) | CYP3A4HTR2C | |
| Hydrochloric Acid SCHEMBL2912094 | 0.63 | HTR2C (0.43) | CYP3A4HTR2CCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | PDE10A 854/4885JAK2 3898/4885JAK1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.